Charles Sternberg, Assistant Editor03.02.21
NAMSA, the 100 percent medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, has acquired Minneapolis-based American Preclinical Services (APS), a full service preclinical CRO. This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January 2021.
With the addition of APS’s portfolio of services, NAMSA will further enhance its already robust preclinical solutions by providing sponsors with a broader range of laboratory models and analysis tools, including surgical instrumentation and several catheterization labs, imaging capabilities and surgical suites. These newly augmented services, delivered within APS’s 130,000 sq. ft. facility, will equip medtech innovators with the capability to perform high-quality safety and performance evaluations for early-stage R&D efforts, as well as an integrated preclinical-to-clinical solution for complex medical device programs.
“APS is excited to join forces with NAMSA, the pioneer and long-standing leader of the medical device testing industry,” commented Michael Conforti, APS president and CEO. “With NAMSA's trusted biocompatibility and biological safety solutions, coupled with both organization’s preclinical services, sponsors now have a clear choice when partnering with the CRO industry’s foremost expert in medical device development and preclinical research,” he concluded.
“NAMSA is extremely pleased to add to its global portfolio of preclinical development solutions through the acquisition of APS,” remarked John Gorski, NAMSA president and CEO. “We are excited to enhance the NAMSA client experience, and also offer APS clients further efficiencies throughout the full development continuum. Together, we look forward to advancing patient healthcare by efficiently and safely helping Sponsors deliver innovative, life-saving medical technology throughout the world,” concluded Gorski.
The acquisition of APS’s Minneapolis preclinical laboratory adds to NAMSA’s rapidly growing global footprint with 13 locations throughout APAC, Europe and North America.
The price and terms of the transaction were not disclosed.
With the addition of APS’s portfolio of services, NAMSA will further enhance its already robust preclinical solutions by providing sponsors with a broader range of laboratory models and analysis tools, including surgical instrumentation and several catheterization labs, imaging capabilities and surgical suites. These newly augmented services, delivered within APS’s 130,000 sq. ft. facility, will equip medtech innovators with the capability to perform high-quality safety and performance evaluations for early-stage R&D efforts, as well as an integrated preclinical-to-clinical solution for complex medical device programs.
“APS is excited to join forces with NAMSA, the pioneer and long-standing leader of the medical device testing industry,” commented Michael Conforti, APS president and CEO. “With NAMSA's trusted biocompatibility and biological safety solutions, coupled with both organization’s preclinical services, sponsors now have a clear choice when partnering with the CRO industry’s foremost expert in medical device development and preclinical research,” he concluded.
“NAMSA is extremely pleased to add to its global portfolio of preclinical development solutions through the acquisition of APS,” remarked John Gorski, NAMSA president and CEO. “We are excited to enhance the NAMSA client experience, and also offer APS clients further efficiencies throughout the full development continuum. Together, we look forward to advancing patient healthcare by efficiently and safely helping Sponsors deliver innovative, life-saving medical technology throughout the world,” concluded Gorski.
The acquisition of APS’s Minneapolis preclinical laboratory adds to NAMSA’s rapidly growing global footprint with 13 locations throughout APAC, Europe and North America.
The price and terms of the transaction were not disclosed.
